6/1/2011

Pfizer reached a settlement with Teva Pharmaceutical Industries that lets the latter continue marketing a generic version of epilepsy medicine Neurontin. Pfizer had said generic Neurontin sold by Teva and its unit Ivax, as well as Actavis Group subsidiary Purepac, infringes a key patent that lasts until 2017.

Full Story:
Bloomberg

Related Summaries